| Literature DB >> 35206049 |
Ronan O' Brien1,2, Maria Hayes1, Gary Sheldrake2, Brijesh Tiwari3, Pamela Walsh4.
Abstract
Population growth is the driving change in the search for new, alternative sources of protein. Macroalgae (otherwise known as seaweeds) do not compete with other food sources for space and resources as they can be sustainably cultivated without the need for arable land. Macroalgae are significantly rich in protein and amino acid content compared to other plant-derived proteins. Herein, physical and chemical protein extraction methods as well as novel techniques including enzyme hydrolysis, microwave-assisted extraction and ultrasound sonication are discussed as strategies for protein extraction with this resource. The generation of high-value, economically important ingredients such as bioactive peptides is explored as well as the application of macroalgal proteins in human foods and animal feed. These bioactive peptides that have been shown to inhibit enzymes such as renin, angiotensin-I-converting enzyme (ACE-1), cyclooxygenases (COX), α-amylase and α-glucosidase associated with hypertensive, diabetic, and inflammation-related activities are explored. This paper discusses the significant uses of seaweeds, which range from utilising their anthelmintic and anti-methane properties in feed additives, to food techno-functional ingredients in the formulation of human foods such as ice creams, to utilising their health beneficial ingredients to reduce high blood pressure and prevent inflammation. This information was collated following a review of 206 publications on the use of seaweeds as foods and feeds and processing methods to extract seaweed proteins.Entities:
Keywords: ACE-1 inhibition; bioavailability; cyclooxygenase enzymes; digestibility; dipeptidyl peptidase IV; extraction methods; health; peptides; seaweed; techno-functional ingredients
Year: 2022 PMID: 35206049 PMCID: PMC8871301 DOI: 10.3390/foods11040571
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Protein extraction technologies applied to seaweeds to disrupt the cell wall.
| Extraction Method | Principle | Advantage | Disadvantage | References |
|---|---|---|---|---|
| Enzyme hydrolysis | Proteolytic/carbohydrase enzymes are applied to degrade polysaccharide components within algal cell walls, releasing target proteins. | Limited use of organic solvents; | Long extraction times; | [ |
| Microwave-assisted extraction | The extraction of target compounds occurs through the application of electromagnetic radiation, resulting in the breakdown of the bonds within the algal cell wall. Rapidly heating the sample solvent mixture results in wide-ranging applicability for the rapid extraction of analytes, including thermally unstable substances. | Environmentally friendly technique as it requires no organic solvents and short extraction times | Use in dried seaweed biomass may be limited. | [ |
| Ultrasound-assisted extraction | The use of an acoustic cavitation technique to produce vapor bubbles in the extraction mixture that contributes to the disruption of polysaccharide components in seaweed biomass, thereby releasing proteins. | Fast processing time, low energy consumption, thermal sensitive technique, and limited use of organic solvents | Potential structural changes within polysaccharide structure. | [ |
| Pulse electric field | The generation of high voltage facilitates protein extraction by electroporation, which disrupts the cell membrane of seaweed. | Non-thermal, energy efficient technique | Limitations on scaling up. | [ |
| Solid–liquid extraction | Utilises different acid and alkaline conditions with water to facilitate the breakdown of hydrogen bonding in algal cell walls. | Simple and cost effective | Partial degradation of the proteins and bioactive components and time consuming. | [ |
Figure 1Schematic diagram indicating enzyme-assisted protein extraction of seaweed using hydrolysing enzymes to rupture the cell wall. This is then proceeded by purification and enrichment techniques such as filtration and molecular weight cut off in order to generate bioactive peptides that can be potentially used in applications in the pharmaceutical and nutraceutical sectors.
Protein extraction methods applied to different seaweeds and reported protein yields (% dry weight).
| Chlorophyta (Green) | |||
|---|---|---|---|
| Seaweed Species | Extraction Methods | Protein Extracted (% Dry Weight) | Reference |
|
| Microwave extraction | 23.9% | [ |
|
| Ultrasound extraction and enzyme extraction (with viscozyme® L, cellulose (EC 232.734.4), alcalase® (EC 3.4.21.14), favourzyme ® (EC 232.752.2) | 16.9−18.8% | [ |
|
| Solvent extraction | 12.28−21.57% | [ |
| Enzyme extraction (with endopeptidase (EC 3.4.21.53), cellulase (EC 3.2.1.4), xylanase (EC 3.2.1.8), β-glucanase (EC 3.2.1.6), arabanase (EC 3.2.1.99) | 24.4% | [ | |
|
| Enzyme extraction (with endopeptidase, cellulase, xylanase, β-glucanase, arabanase) | 6.2–10.1% | [ |
|
| Enzyme extraction (with papain (EC 3.4. 22.2)) | 69.19% | [ |
|
| pH shift extraction (with pH 2 and pH 13) | 22.7% | [ |
|
| |||
|
|
|
|
|
|
| Autoclave | 21.5% | [ |
|
| Chemical extraction | 22.5% | [ |
|
| Osmotic shock | 35.5% | [ |
|
| Enzyme extraction (with cellulose) | 7.1% | [ |
|
| Homogenisation and protein precipitation | 8.9% | [ |
|
| Enzyme extraction (with Celluclast (EC 232-734-4), Shearzyme®, alcalase®, and viscozyme®) | 35.5–41.6% | [ |
|
| Enzyme extraction (with UmamizymeTM and xylanase) | 33.4% | [ |
|
| Enzyme extraction (with Prolyve®1000, and flavourzyme®) | 23% | [ |
|
| Enzyme extraction (with α-amylase, cellulose, and pectinase) | 36.1% | [ |
|
| |||
|
|
|
|
|
|
| High-pressure extraction | 23.7% | [ |
|
| Autoclave extraction | 24.3% | [ |
|
| High-pressure extraction | 15% | [ |
|
| Autoclave extraction | 17.1% | [ |
|
| Chemical extraction | 9% | [ |
|
| Chemical extraction | 8–12.2% | [ |
|
| Chemical extraction | 7.97–16.90% | [ |
|
| Chemical extraction | 6.5% | [ |
| Enzyme extraction (with cellulose and β-glucosidase) | 10.2% | [ | |
|
| Enzyme extraction (with AMG, Celluclast, Dextrozyme, Promozyme®, viscozyme®, alcalase®, flavourzyme®, Neutrase, Protamex®, and pepsin (EC 3.4.23.1) | 6.94–22.5% | [ |
Figure 2Schematic diagram indicating the pH shift and microwave-assisted extraction (MAE) procedures in order to disrupt the anionic cell wall in seaweeds. The acid/base is added, fractionising the sample into smaller fragments which are centrifuged and later cleaned up and filtered using a molecular weight cut-off filter membrane. The peptides are screened for anti-hypertensive, anti-diabetic and anti-inflammatory activities. Additionally, the peptides are characterised using mass spectrometry, and they can be used in the functional foods, as well as the cosmetic and pharmaceutical sectors.
Bioactivities reported previously for seaweed-derived bioactive peptides (IC 50 µM: the concentration of inhibitory peptides required to inhibit 50% of the enzyme).
| Chlorophyta (Green) | |||||
|---|---|---|---|---|---|
| Seaweed Species | Extraction Process | Reported Bioactivity | Amino Acid Sequence | IC50 | Reference |
|
| Osmotic shock/precipitation with ammonium sulphate and papain (EC 3.4. 22.2) hydrolysis | Renin inhibition | None reported | None reported | [ |
| Enzyme hydrolysis with purazyme, flavourzyme (E.C. | Anti-inflammatory | None reported | None reported | [ | |
|
| Enzyme hydrolysis with alcalase® (E.C. 3.4.21.14), pH 7.6, 90 min, 25 °C//10 min, 100 °C | ACE-1 inhibition | PAFG | 35.9 μM | [ |
|
| Enzyme hydrolysis with trypsin (EC 3.4.21.4) + pepsin + papain, pH 8.42, 5 h, 28.5 °C | ACE-1 inhibition | FGMPLDR, | 219.35 μM, | [ |
|
| Enzyme hydrolysis with pepsin (E.C. 3.4.23.1) (E:S 1), pH 2, 20 h, 37 °C//bromelain (E:S 1), pH 7, 20 h, 37 °C | ACE-1 inhibition | IP, | 0.020 mg/mL, | [ |
|
| Osmotic shock/precipitation with ammonium sulphate and papain (EC 3.4. 22.2) hydrolysis | Renin inhibition | None reported | None reported | [ |
| Enzyme hydrolysis with purazyme, flavourzyme (EC. | Anti-inflammatory | None reported | None reported | [ | |
|
| |||||
|
|
|
|
|
|
|
|
| Enzyme hydrolysis with alcalase® (E.C. 3.4.21.14) and flavourzyme® (E:S 1), pH 7, 4 h, 50 °C | DPP IV inhibitory activity | WLVA | 439 μM | [ |
|
| Enzyme hydrolysis with alcalase® and favourzyme® (E:S 1), pH 7, 4 h, 50 °C | ACE-1 inhibition | DYYLR, | 551 μM, | [ |
|
| Ion exchange and gel filtration method | ACE-1 inhibition | IY, | 2.69 μM | [ |
|
| Enzyme hydrolysis with pepsin (EC 3.4.23.1), 5 h, 45°C | anti-coagulant activity | NMEKGSSSVVSSRM | 0.3 µM | [ |
|
| Enzyme hydrolysis with corolase PP, pH 7,4 h, 50 °C | Antioxidant | FITDGNK, | None reported | [ |
|
| Enzyme hydrolysis with thermolysin, pH 8, 3 h,70 °C | ACE-1 inhibition | LDY, | 0.14 µM | [ |
|
| Enzyme hydrolysis with alcalase® | ACE-1 inhibition | n/a | 1.6 g/L | [ |
|
| Enzyme hydrolysis with alcalase® | ACE-1 inhibition | n/a | 0.516 g/L | [ |
|
| Osmotic shock/ precipitation with ammonium sulphate and papain hydrolysis | Renin inhibition | IRLIIVLMPILMA | 3.344 mM | [ |
|
| Enzyme hydrolysis with papain | PAF-AH inhibition | NIGK | 2.32 mM | [ |
|
| Enzyme hydrolysis with pepsin (E:S 8), pH 2, 4 h, 37 °C and viscozyme® | α-amylase inhibition | GGSK | 2.58 mM | [ |
|
| Chemically synthesised and purified by HPLC | COX-2 inhibition | PPY1 | n/a | [ |
|
| |||||
|
|
|
|
|
|
|
|
| Enzyme hydrolysis with protease S “amano” pH 8, 18 h, 70 °C | ACE-1 Inhibition | VY, | 35.2 μM, | [ |
|
| Enzyme hydrolysis with pepsin, pH 2, | ACE-1 Inhibition | SKTY, GKY, SVY | 8.12μM, | [ |
|
| Enzyme hydrolysis with trypsin (E:S 0.05), pH 7, 24 h, 30 °C | Anti-bacterial activity | TITLDVEPSDTIDGVK, ISGLIYEER, MALSSLPR, ILVLQSNR, ISAILPSR, IGNGGELR, LPDAALN, EAESSLTGGNGCAK, QVHPDTGISK | None reported | [ |
|
| Enzyme hydrolysis with alcalase® (60°C, pH 8) | ACE inhibition | KY, | 5.24 μM, | [ |
|
| Ultrasound and subcritical water | α-amylase inhibition | LRSELAAWSR | 313.6 μg/mL | [ |
|
| Ultrasound and subcritical water | α-glucosidase | LRSELAAWSR | 134.2 μg/mL | [ |
|
| Enzyme hydrolysis with pepsin and papain | ACE-1 inhibition | RWDISQPY | 72.24 μM | [ |
Uses of different seaweed in human food.
| Seaweed Species | Product | Function | Reference |
|---|---|---|---|
|
| Semi sweet biscuits | Functional antioxidant | [ |
|
| Fish surimi | Functional and antioxidant effects | [ |
|
| Pork patties | Natural antioxidants | [ |
|
| Pork patties | Natural antioxidants | [ |
|
| Meat based products | Antioxidant | [ |
|
| Breadsticks | Functional ingredient | [ |
|
| White bread | Antioxidant | [ |
|
| Pasta | Functional ingredient | [ |
|
| Milk | Functional ingredient | [ |
| Fish feed | Functional ingredient | [ | |
| Animal feed | Functional ingredient | [ | |
|
| Fish feed | Functional ingredient | [ |
|
| Food colouring | Functional ingredient | [ |
Figure 3Schematic diagram of the renin–angiotensin–aldosterone system (RAAS), the kinin–kallikrein system and the anti-hypertensive effect of ACE. The protein angiotensinogen is formed in the liver and renin aspartic protease protein causes the breakdown of angiotensinogen into the decapeptide angiotensin I. Through the cleaving action of ACE-1, angiotensin I is converted into angiotensin II, whose action recruits the second messenger 1,4,5-inositol trisphosphate (IP3), resulting in the formation of calcium ions (Ca2+), leading to an increase in blood pressure through vasoconstriction. In the adrenal cortex, the secretion of angiotensin II enhances the production of aldosterone that causes the formation of extracellular fluid, thereby increasing blood pressure. Bradykinin a peptide produced through enzyme action of kallikrein, it is inactivated by ACE-1 and enhances the release of calcium ions [223]. Immune-regulating lipids and prostaglandins signal the opening of arteries in the heart through vasodilation, alleviating blood pressure [224].
Figure 4Schematic diagram showing the role of platelet-activating factor acetylhydrolase (PAF-AH) in cardiovascular disease. PAF-AH is a catabolic enzyme residing in immune cells such as macrophages and lipoproteins such as apolipoprotein β lipoproteins. Upon secretion of plasma PAF-AH, they actively oxidise apolipoprotein β-containing lipoproteins in the blood into two inflammatory mediators, lysophosphatidylcholine and oxidised non-esterified fatty acids (oxNEFAs). The formation of these molecules simulates the rapid production of diseased tissue which contribute to the blocking of arteries and transportation of blood to essential organs such as the heart and brain, leading to necrosis. Through the oxidation of PAF-AH, its activity can be inhibited by seaweed-derived bioactive peptides and statin drugs, thus preventing the onset of strokes and other cardiovascular events.
Figure 5Schematic diagram of the arachidonic pathway and the inflammatory action of cyclooxygenase (COX) enzymes. Arachidonic acid is a polyunsaturated fatty acid which is converted into eicosanoid molecules prostaglandin and thromboxane by the rate-limiting enzymes, COX-1 and COX-2 [296]. The eicosanoid fatty acids prostaglandin and thromboxane are particularly involved in essential inflammation-related activities including the formation of bone and regulation of blood flow and platelets [297]. Non-steroidal anti-inflammatory drugs (NSAIDs) specifically target COX-1 and COX-2 activity. Eicosanoid vasodilator prostacyclin is targeted by NSAIDs, resulting in decreased blood pressure through vasodilation [298]. Thromboxane, another target of NSAIDs, increases blood pressure through vasoconstriction and increases the formation of platelets [299].